REPEAT – TAAT® ships largest UK shipment ever to expand distribution, The Canadian Business Journal

The largest UK shipment of TAAT® to date is expected to arrive this quarter and our UK TAAT® distributor plans to expand the brand’s footprint into other markets in the South East region of the country. increase.

LAS VEGAS AND VANCOUVER, BC, SEPTEMBER 19, 2022 (GLOBE NEWSWIRE) — TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (“We” or “TAAT®”) announces the delivery of a ‘full container’ shipment of TAAT® to the UK. This is about three times the amount of product previously sent, making it the UK’s largest shipment to date. This shipment will be used to further expand the distribution of his TAAT® outside the Greater London region into additional markets in the South East region of the UK. We are currently coordinating with our UK wholesale partner Green Global Earth (“GGE”). .

TAAT® Chief Executive Officer Michael Saxon commented: The specific challenges he faces in his supply chain are common, especially with new products like his TAAT®. We believe we have reached the end of these early hurdles and can start shipping to the UK on a more regular basis as our first international market. We are working directly with our partners to plan exactly how to execute our future expansion within the UK and will return later this year to discuss our plans for 2023. “

TAAT® CEO Michael Saxon (left) and GGE CEO John Hilton (right) pose for a photo at the InterTabac trade fair in Dortmund, Germany. Mr Saxon and Mr Hilton are now preparing to receive their largest shipment to date from the company, and are committed to TAAT® and GGE’s resources to optimize the growth-stage commercialization of TAAT® products in the UK. is being adjusted.

Readers using news aggregation services may not be able to view the above media. SEDAR or PR for investors Please see the section on our website for a version of this press release including all published media.

In a press release dated July 22, 2022, TAAT® announced that it has received a third reorder from GGE, who were particularly keen to receive TAAT® made with Beyond Tobacco™ “V3”. Adult smokers in the US and UK found that the smoking experience of V3 was enjoyable and very similar to the experience of smoking regular cigarettes, despite being nicotine-free. At the time of this writing, TAAT® is mainly sold in South London. The Company and GGE intend to leverage to organically establish an expanded footprint in new markets in neighboring regions.

On behalf of our Board of Directors,

TAAT® GLOBAL ALTERNATIVES INC.

“Michael Saxon”

Michael Saxon, CEO and Director

For more information, please contact:

TAAT® Investor Relations
1-833-TAAT-USA (1-833-822-8872)
[email protected]

The Canadian Stock Exchange (“CSE”) has not reviewed and is not responsible for the accuracy or adequacy of this release.

About TAAT® Global Alternatives Co., Ltd.

TAAT® develops, manufactures and markets alternative products in categories such as tobacco, hemp, kratom and other emerging CPG segments. The company’s flagship products are nicotine-free/tobacco-free, combustible products with a patent-pending matrix formulation that are sold in thousands of stores across the United States. With more than $80 million in annual gross revenue, TAAT® facilities include an operations center in Nevada, a distribution center in Ohio and multiple convenience stores.

For more information, see: http://taatglobal.com.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. In many cases, but not always, forward-looking information and information are referred to as “plans,” “expects,” “does not expect,” “anticipates,” “estimates,” “intends,” ” anticipate, “unexpect,” or “believe,” or variations of such words or phrases, or that a particular action, event, or outcome “could,” “could,” “could,” Saying “could”, “could”, or “could” be taken, occurred or achieved. The forward-looking information in this news release includes, in addition to the following, statements regarding the expected performance of his TAAT® in the tobacco industry. Potential outcomes from his TAAT® marketing and commercialization efforts in the UK, aimed at adult smokers in Greater London and the retailers from whom they typically purchase tobacco products. Forward-looking information reflects management’s current expectations based on information currently available and includes many statements that could cause results to differ materially from those described in the forward-looking information. Subject to risk and uncertainty. Although we believe that the assumptions and factors used in preparing forward-looking information are reasonable, we should not place undue reliance on such information and that such There is no guarantee that it will occur within the disclosed time frame or that it will not occur at all. Factors that could cause actual results or events to differ materially from current expectations include: (ii) the growth and changing size of the tobacco market; (iii) changes in the regulatory landscape that applies to our business; (iv) other factors beyond our control. We operate in a rapidly evolving environment. Because new risk factors emerge from time to time, it is not possible for our management to predict all risk factors, and we cannot predict the impact that all of them will have on our business and what factors or combinations of factors may be. It is also not possible to assess the extent of the impact. It could cause actual results to differ from those contained in the forward-looking information. The forward-looking information contained in this news release is made as of the date of this news release and the Company may, as a result of new information, future events or otherwise, make forward-looking information. We expressly disclaim any intention or obligation to update or revise. except where required by applicable law.

Statements in this news release have not been evaluated by Health Canada or the US Food and Drug Administration. Because each individual is different, the benefits, if any, of taking our products will vary from person to person. We cannot make any claims or warranties regarding the effects of our products on your personal health and well-being. Our products are not intended to diagnose, treat, cure, or prevent disease.

This news release generally includes (i) the company’s relationship with the third party entity mentioned in this release and/or (ii) the client/vendor/company whose relationship with the company is mentioned in this release. Service Provider Party. All rights to such trademarks are reserved by their respective owners or licensees.

Third Party IR Company Statement

Disclosures about the investor relations firm maintained by TAAT® Global Alternatives Inc. can be found under the company profile at: http://sedar.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2ae91b47-69c4-45c8-8187-168ea8c5668e.

CBJ Newsmaker